Marieke van Rosmalen

84. Garg N, Park SB, Howells J, et al. Conduction block in immune-mediated neuropathy: paranodopathy versus axonopathy. Eur. J. Neurol. 2019;26:1121–1129. 85. Straver DCG, VanAsseldonk JTH, Notermans NC, et al. Cold paresis in multifocal motor neuropathy. J. Neurol. 2011;258:212–217. 86. Soliven B. Animal models of autoimmune neuropathy. ILAR J. 2014;54:282–290. 87. Susuki K, Nishimoto Y, Yamada M, et al. Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons. Ann. Neurol. 2003;54:383–388. 88. Piepers S, JansenMD, Cats EA, et al. IVIg inhibits classical pathway activity and anti-GM1 IgM- mediated complement deposition in MMN. J. Neuroimmunol. 2010;229:256–262. 89. Uncini A, Santoro M, Corbo M, et al. Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies. Muscle Nerve 1993;16:610–615. 90. TringaleK, NguyenT, Bahrami N, et al. Identifying early diffusion imaging biomarkers of regional white matter injury as indicators of executive function decline following brain radiotherapy: A prospective clinical trial in primary brain tumor patients. Radiother Oncol 2019;132:27–33. 91. Farinas AF, Esteve IVM, Pollins AC, et al. Diffusion Magnetic Resonance Imaging Predicts Peripheral Nerve Recovery in a Rat Sciatic Nerve Injury Model. Plast. Reconstr. Surg. 2020;145:949–956. 92. Warman Chardon J, Straub V. The Role of Muscle Imaging in the Diagnosis andAssessment of Children with Genetic Muscle Disease. Neuropediatrics 2017;48:233–241. 93. Ponrartana S, Ramos-Platt L, Wren TAL, et al. Effectiveness of diffusion tensor imaging in assessing disease severity in Duchenne muscular dystrophy: preliminary study. Pediatr. Radiol. 2015;45:582–589. 94. Durmus H, Yilmaz R, Gulsen-Parman Y, et al. Muscle magnetic resonance imaging in spinal muscular atrophy type 3: Selective and progressive involvement. Muscle andNerve 2017;55:651–656. 95. Otto L, FroelingM, van EijkR, et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI – a pilot study. NMR Biomed. 2021;in press 96. Telleman J, Herraets I, Goedee H, et al. Prognostic value of nerve ultrasound: a prospectivemulticenter study on the natural history of polyneuropathy. Eur. J. Neurol. 2021;in press 97. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 2018;14:577–589. 98. Mariotto S, FarinazzoA, Magliozzi R, et al. Serum and cerebrospinal neurofilament light chain levels in patients with acquired peripheral neuropathies. J. Peripher. Nerv. Syst. 2018;23:174–177. 99. Graham RC, Hughes RAC. Amodified peripheral neuropathy scale: The Overall Neuropathy Limitations Scale. J. Neurol. Neurosurg. Psychiatry 2006;77:973–976. 100. van Lieverloo GGA, Wieske L, Verhamme C, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 2019;24:187–194. 101. Nes S Van, Vanhoutte E, van Doorn P, et al. Rasch-built Overall Disability Scale (R-ODS) for immune-medicated peripheral neuropathies. Int. Classif. 2011;76:337–345. 102. Blok JH, RuitenbergA, Maathuis EM, Visser GH. The electrophysiological muscle scan. Muscle and Nerve 2007;36:436–446. 103. Maathuis EM, Drenthen J, Van Doorn PA, et al. The CMAP scan as a tool to monitor disease progression inALS and PMA.Amyotroph. Lateral Scler. Front. Degener. 2013;14:217–223. 104. Okhovat AA, Advani S, Moradi K, et al. Application of CMAP scan for the evaluation of patients with chronic inflammatory demyelinating polyneuropathy: a prospective study. Clin. Neurophysiol. 2021;online ahead of print.